Welcome to our dedicated page for Anavex Life Scie news (Ticker: AVXL), a resource for investors and traders seeking the latest updates and insights on Anavex Life Scie stock.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. The AVXL news feed highlights company announcements related to its precision-medicine programs in Alzheimer’s disease, Parkinson’s disease dementia, Rett syndrome, schizophrenia, and other central nervous system (CNS) conditions.
News about Anavex often covers clinical trial milestones for its lead candidate ANAVEX ae2-73 (blarcamesine), including Phase 2a and Phase 2b/3 studies in Alzheimer’s disease, proof-of-concept data in Parkinson’s disease dementia, and trials in adult and pediatric Rett syndrome. Updates also address regulatory interactions, such as communications with the European Medicines Agency and the U.S. Food and Drug Administration regarding early Alzheimer’s disease, and the company’s plans to pursue re-examination procedures or further dialogue.
Investors and followers can also find coverage of ANAVEX ae3-71, which targets SIGMAR1 and M1 muscarinic receptors and has been studied in schizophrenia, as well as information on peer-reviewed publications, scientific conference presentations, and participation in initiatives like the ACCESS-AD consortium in Europe. Corporate developments, including financial results, business updates, and senior leadership appointments, are regularly reported.
This AVXL news page brings together these disclosures so readers can track how Anavex’s clinical data, regulatory discussions, collaborations, and corporate actions evolve over time. For those monitoring CNS drug development and precision-medicine approaches, the stream of press releases and related items offers context on the company’s progress and areas of focus.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced the approval from the Australian Human Research Ethics Committee to begin a First-in-Human (FIH) clinical study of ANAVEX®3-71 (AF710B). This orally-administered small molecule targets sigma-1 and M1 muscarinic receptors, aiming to treat Frontotemporal Dementia (FTD). ANAVEX®3-71 has shown disease-modifying activity against Alzheimer's disease hallmark features in preclinical studies. The Phase 1 trial will involve 36 healthy subjects to assess safety and pharmacokinetics, followed by extended dosing in FTD patients.
Anavex Life Sciences Corp. (Nasdaq: AVXL) provided an update on its financial results for Q2 of fiscal 2020. The company reported a net loss of $7.2 million, or $0.12 per share, consistent with the prior year's loss of $7.2 million but an improvement in loss per share. Cash and cash equivalents increased to $26.6 million from $22.2 million. Clinical trials for ANAVEX®2-73 (blarcamesine) are progressing, with enrollment for the Phase 2 trials in Parkinson’s disease dementia and Rett syndrome exceeding 50%. Topline results for the Parkinson’s trial are expected by mid-2020.
Anavex Life Sciences Corp. (Nasdaq: AVXL) has announced it will release its financial results for the fiscal quarter ending March 31, 2020, on May 7, 2020. This will be followed by a conference call at 4:30 PM ET to discuss the results and updates on clinical programs. Anavex is focused on developing therapeutics for neurodegenerative diseases, including Alzheimer's and Parkinson's. Their leading candidate, ANAVEX®2-73 (blarcamesine), has shown promise in clinical trials and is aimed at restoring cellular homeostasis.